Do Hung 4
4 · AMICUS THERAPEUTICS, INC. · Filed Feb 14, 2020
Insider Transaction Report
Form 4
Do Hung
Sr Vice President Discovery
Transactions
- Exercise/Conversion
Common Stock
2020-02-12$8.61/sh+6,300$54,243→ 527,455 total - Exercise/Conversion
Common Stock
2020-02-12$6.10/sh+29,148$177,803→ 556,603 total - Exercise/Conversion
Common Stock
2020-02-12$5.13/sh+17,652$90,555→ 574,255 total - Sale
Common Stock
2020-02-12$11.01/sh−63,356$697,340→ 510,899 total - Exercise/Conversion
Stock Options (right to buy)
2020-02-12−6,300→ 43,700 totalExercise: $8.61Exp: 2025-01-02→ Common Stock (6,300 underlying) - Exercise/Conversion
Stock Options (right to buy)
2020-02-12−29,148→ 6,270 totalExercise: $6.10Exp: 2026-06-15→ Common Stock (29,148 underlying) - Exercise/Conversion
Stock Options (right to buy)
2020-02-12−17,652→ 19,133 totalExercise: $5.13Exp: 2027-01-03→ Common Stock (17,652 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.00 to $11.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]All of the options were fully vested and exercisable as of February 12, 2020.
- [F4]As of February 12, 2020, 45,812 options were fully vested and exercisable and 4,188 remained unvested from this grant.
- [F5]As of February 12, 2020, 20,594 options were fully vested and exercisable and 16,191 remained unvested from this grant.